Skip to content
JCP
PCC
News
CME
About
Authors & Reviewers
Sign In
Subscribe
Search
Advanced Search
Menu
JCP
PCC
News
CME
About
Authors & Reviewers
Sign In
Subscribe
Sign in
Subscribe
Clinical Topics
View All
Addiction
ADHD
Alzheimer’s Disease
Anxiety
Bipolar Disorder
Depression
Movement Disorders
Neurology
OCD
Psychopharmacology
PTSD and Trauma
Schizophrenia/Schizoaffective Disorders
Sleep
Tardive Dyskinesia
View All
Collections
View All
Academic Highlights
Auvelity: Information from Industry
Banner Alzheimer’s Institute
Clinical & Practical Psychopharmacology
Early Career Psychiatrists
Focus on Childhood and Adolescent Mental Health
Focus on Geriatric Psychiatry
Focus on Psychotherapy
Focus on Suicide
Focus on Psychosis
Focus on Women’s Mental Health
Rounds in the General Hospital
UZEDY: Information from Industry
View All
InfoPack
Recent JCP Articles on InfoPack
JCP
InfoPack
Emerging Treatments in Schizophrenia
February 15, 2022
Experts discuss the brain circuits involved in schizophrenia, the current medications, and new agents in phase 3 trials that do not directly block postsynaptic D2 receptors. Phase 2 data...
Christoph U. Correll
,
Anissa Abi-Dargham
,
Oliver Howes
JCP
InfoPack
Improving Outcomes in Patients With Bipolar Depression: A Comprehensive Review
March 25, 2015
Andrew A. Nierenberg
,
Gary S. Sachs
,
Roger S. McIntyre
JCP
InfoPack
Clinical and Cost Implications of Treating Schizophrenia: Safety, Efficacy, Relapse Prevention, and Patient Outcomes
August 26, 2014
Mark Olfson
,
John M. Kane
,
Christoph U. Correll
, et al
Recent PCC Articles on InfoPack
news
Where Autoantibodies Strike in Anti-NMDAR Encephalitis
January 26, 2026
A new study shows that antibodies in anti-NMDAR encephalitis target exposed hotspots on NMDA receptors, explaining synaptic disruption.
JCP
ASCP Corner
Rethinking Amisulpride: Could N-Methylation Result in a New and Even Better Antipsychotic?
January 26, 2026
This article will familiarize US clinicians with amisulpride’s history and data, and the rationale behind development of LB-102, an N-methylated analogue of amisulpride.
John M. Kane
,
Christoph U. Correll
JCP
Letter to the Editor
Urological Commentary on Ketamine-Associated Uropathy
January 26, 2026
The author comments on a recent article reviewing ketamine-associated uropathy in therapeutic and nontherapeutic settings.
Asem Abdelrahman
Featured
InfoPack Research
JCP
Letter to the Editor
Ketamine-Associated Uropathy in Therapeutic Contexts: Reply to Abdelrahman
January 26, 2026
Dr Andrade responds to a letter commenting on his recent review of ketamine-associated uropathy in therapeutic and nontherapeutic settings.
Chittaranjan Andrade
news
Weekly Mind Reader: When Antidepressants Fail
January 23, 2026
New Mayo Clinic guidance stresses patient care, while studies examine veterans’ cannabis use and reject lowering the DSM-5-TR mixed-features threshold.
news
How Delusions Take Shape
January 22, 2026
A new study finds that early psychosis delusions emerge as emotionally grounded, embodied responses shaped by lived experience and relationships.
